← Back to Search

Local Anesthetic

Nerve Block for Pain Management

Phase < 1
Recruiting
Led By Morgan Ritz, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to study procedure end (approximately 30 minutes)
Awards & highlights
No Placebo-Only Group

Summary

This trial will use a nerve block to help with pain relief and reduce need for opiates in patients with rib fractures, vertebral fractures, pancreatitis, etc.

Who is the study for?
This trial is for adults with certain painful conditions like rib or vertebral fractures, pancreatitis, pancreatic cancer, renal colic, and back pain. It's not suitable for those with unstable vital signs, skin infections at the injection site, allergies to local anesthetics, pregnant women or individuals under 18.
What is being tested?
The study tests if injecting Bupivacaine into the erector spinae muscles can help manage pain from specific conditions and reduce the need for opioid painkillers after treatment.
What are the potential side effects?
Possible side effects of Bupivacaine include numbness in treated areas, weakness in legs if used on back pain patients, low blood pressure, nausea or vomiting. Rarely it may cause severe allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to study procedure end (approximately 30 minutes)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to study procedure end (approximately 30 minutes) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain Scale Rating

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Erector Spinae Plane Block (ESP) administrationExperimental Treatment1 Intervention
Patients with the listed diagnoses will be offered and then consented for an ESPB under ultrasound guidance.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine Injection
2017
Completed Phase 4
~580

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
476 Previous Clinical Trials
92,935 Total Patients Enrolled
Morgan Ritz, MDPrincipal InvestigatorUniversity of Texas Health Science Center San Antonio
~15 spots leftby Aug 2025